Form 4: Fennec Pharmaceuticals CEO Rosty Raykov Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Fennec Pharmaceuticals CEO Rostislav Raykov sold a total of 88,583 common shares between April 4th and April 5th, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Rostislav Raykov, CEO of Fennec Pharmaceuticals, sold shares of the company's common stock.
- The sales occurred on April 4th and April 5th, 2024.
- A total of 88,583 shares were sold in three separate transactions.
- The sales were executed under a pre-arranged 10b5-1 trading plan established on December 14, 2023.
- The prices per share ranged from $10.751 to $10.8943.
- Following these transactions, Raykov directly owns 187,471 shares of Fennec Pharmaceuticals.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock sales by an executive. The use of a 10b5-1 plan suggests the sales were pre-planned and not based on any inside information, so the sentiment is neutral.
Industry Context
Sales by company executives are a normal part of corporate governance. The use of a 10b5-1 plan suggests the sales were pre-planned and not based on any inside information.
Stakeholder Impact
- Shareholders may react to the news of the CEO selling shares, although the pre-planned nature of the sales mitigates potential concerns.
Key Dates
| Date | Description |
|---|---|
| December 14, 2023 | Date of the 10b5-1 trading plan |
| April 04, 2024 | Date of first reported transaction |
| April 05, 2024 | Date of last reported transaction and filing date |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.